Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US8292141053
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BS2ZD1
SLP
Simulations Plus Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Health Information Services · THEMEFOLIO: $HLTH
NAME
Simulations Plus Inc
ISIN
US8292141053
TICKER
SLP
MIC
XNAS
REUTERS
SLP.OQ
BLOOMBERG
SLP US
Di., 11.11.2025       Simulations Plus
US8292141053

NEWTOWN, Pa., Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. ("Simulations Plus") (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Simulations Plus
US8292141053

NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 23.10.2025       Simulations Plus
US8292141053

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 22.10.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and managemen...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 16.10.2025       Simulations Plus
US8292141053

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations P...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Sa., 11.10.2025       Simulations Plus
US8292141053

NEW YORK, Oct. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 06.10.2025       Simulations Plus
US8292141053

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf o...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 24.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 19.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 12.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 09.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 01.09.2025       Simulations Plus
US8292141053

NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the following investor events...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 25.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 22.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Sa., 16.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 11.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 08.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 8, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Sa., 02.08.2025       Simulations Plus
US8292141053

NEW YORK, Aug. 2, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Simulations Plus
US8292141053

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Simulations Plus
US8292141053

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the I...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 28.07.2025       Simulations Plus
US8292141053

NEW YORK, July 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting f...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 27.07.2025       Simulations Plus
US8292141053

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 27.07.2025       Simulations Plus
US8292141053

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 25.07.2025       Simulations Plus
US8292141053

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulati...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 22.07.2025       Simulations Plus
US8292141053

NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 20...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 18.06.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the t...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 12.06.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 11.06.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue gu...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 05.06.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, op...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 15.05.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platfo...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 21.04.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration’s (FDA) recently announced roadmap for reducing animal...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financia...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 20.03.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday,...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 10.03.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBan...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 04.02.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attend...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 22.01.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 13.01.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approve...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Manag...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conferen...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink